Tranilast

Research use only, not for human use.

A compound that exhibits anti-inflammatory and immunomodulatory effects by inhibiting lipid mediator and cytokine release from inflammatory cells and interfering with PDGF- and TGF-β1-induced proliferation and migration of vascular medial smooth muscle cells.

A compound that exhibits anti-inflammatory and immunomodulatory effects by inhibiting lipid mediator and cytokine release from inflammatory cells and interfering with PDGF- and TGF-β1-induced proliferation and migration of vascular medial smooth muscle cells; inhibits endotoxin-induced PGE2 (IC50=1-20 uM), thromboxane B2 (IC50= 10-50 uM), TGF-β1 (IC50=100-200 uM), and IL-8 (IC50=100 uM) formation, but has no effect on TNF-α; also inhibits VEGF-induced angiogenetic activities.Allergy Approved.

Cell Proliferation Assay Cell Line:MCF-7 and MDA-MB-231 cells Concentration:10, 20, 50, 100, and 200 μMIncubation Time:48 hours Result:Anti-proliferative effect in a dose-dependent manner in both cell lines.Cell Viability Assay Cell Line:Human dermal microvascular endothelial cells (HDMECs) Concentration:12.5, 25, 50, 100 μg/mL Incubation Time:72 hours Result:IC50 value was 44.3 μg/mL (136 μM).

Animal Model:Nine-week-old male C57BL/6 miceDosage:300 mg/kg Administration:Administered orally twice a day for 3 days Result:Suppressed the VEGF-induced angiogenesis in matrigel; 58% of significant suppression was observed at a dose of 300 mg/kg. The ED50 value and 95% confidence limits were 165 mg/kg and 162±169 mg/kg, respectively.

MK-341 | SB-252218

Others

Other Targets

Others

Inflammation/Immunology

——

53902-12-8

327.3

C18H17NO5

>98% (HPLC)

DMSO: 32.7 mg/mL (100 mM) （ < 1 mg/ml refers to the product slightly soluble or insoluble )

COC1=C(C=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O)OC

Benzoic acid, 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]- (9CI)

(-20℃)

With Ice Pack

≥ 2 years